Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 (Zibotentan) 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients

NCT00626548 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00626548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00626548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 (Zibotentan) 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2008
Completion date
May 31, 2011
Enrollment
2,577 (actual)
Sites
322

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer